- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal: Potential kidney protective effects of glucagon-like peptide-1 receptor agonists. (Pubmed Central) - Jul 20, 2024
It has also been reported by the sponsors of the trial that the primary end point of the trial was reduced by 24% with both CKD and CV outcomes contributing to risk reduction. In anticipation of the results of the FLOW trial being published, we review the current evidence surrounding kidney outcomes and proposed kidney protective pathways associated with GLP-1RA use.
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal: Semaglutide and obesity: beyond the nutritional and lifestyle intervention? (Pubmed Central) - Jul 19, 2024
Data in the literature on the anti-obesity action of semaglutide are available for both routes of administration of the drug, with a prevalence of studies using the s.c. one. However, given its dosage, oral semaglutide may provide greater attractiveness and better treatment adherence, but further research is needed in this field.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) (clinicaltrials.gov) - Jul 18, 2024
P3, N=568, Active, not recruiting,
However, given its dosage, oral semaglutide may provide greater attractiveness and better treatment adherence, but further research is needed in this field. Recruiting --> Active, not recruiting
- |||||||||| Marizev (omarigliptin) / Merck (MSD)
Trial initiation date, HEOR, Real-world evidence, Real-world: Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (clinicaltrials.gov) - Jul 17, 2024
P4, N=938, Not yet recruiting,
99% of participants, and in increased numbers in those with higher NAS and fibrosis stages.This is an encore of an abstract that will be presented for the first time at the European Association for the Study of the Liver (EASL) Congress, 5 Initiation date: Jun 2024 --> Sep 2024
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Semaglutide and NYHA Functional Class (Pubmed Central) - Jul 10, 2024
P3
Initiation date: Jun 2024 --> Sep 2024 In patients with obesity-related HFpEF, fewer semaglutide-treated than placebo-treated patients had a deterioration, and more had an improvement, in NYHA functional class at 52
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Wernicke Encephalopathy Associated With Semaglutide Use. (Pubmed Central) - Jul 8, 2024
Alcoholic Wernicke encephalopathy (WE) is also another common manifestation of neurological dysfunction; however, the prevalence of non-alcoholic WE is relatively uncommon. We discuss a 37-year-old male who presented to the ED with dysphagia, slurred speech, word-finding difficulty, and restricted extraocular movements from non-alcoholic WE in the setting of semaglutide use.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Case report: Nerve fiber regeneration in children with melanocortin 4 receptor gene mutation related obesity treated with semaglutide. (Pubmed Central) - Jul 8, 2024
Both children were treated with once weekly semaglutide for 6 months with no change in weight, and only a minor improvement in HbA1c and lipid profile. However, there was evidence of nerve regeneration with an increase in corneal nerve fiber density (CNFD) [child A (13.9%), child B (14.7%)], corneal nerve branch density (CNBD) [child A (110.2%), child B (58.7%)] and corneal nerve fiber length (CNFL) [child A (21.5%), child B (44.0%)].
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Single-center experience of effect of GLP-1 receptor agonists in adults with cystic fibrosis (104 AB) - Jul 4, 2024 - Abstract #NACFC2024NACFC_324;
With the addition of GLP-1-RAs, all experienced weight loss and a reduction in daily insulin dose, and most had improvement in pulmonary function. GLP-1-RA tolerability was similar to that reported in people without CF with diabetes or obesity treated with these agents.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open, Trial initiation date, Real-world evidence, Real-world: Special Use - Results Surveillance on Long-term Use With Wegovy (clinicaltrials.gov) - Jul 3, 2024
P=N/A, N=1000, Enrolling by invitation,
Recruiting --> Active, not recruiting Not yet recruiting --> Enrolling by invitation | Initiation date: Feb 2024 --> Jun 2024
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
PK/PD data, Review, Journal: Clinical Pharmacokinetics of Semaglutide: A Systematic Review. (Pubmed Central) - Jul 2, 2024
Food and various dosing conditions including water volume and dosing schedules can affect the oral semaglutide exposure...The existing pharmacokinetic data can assist in developing and evaluating pharmacokinetic models of semaglutide and will help clinicians predict semaglutide dosages. In addition, it can also help optimize future clinical trials.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
Journal: Time to unshackle the medical treatment of obesity in the NHS. (Pubmed Central) - Jun 27, 2024
In addition, it can also help optimize future clinical trials. The glucagon-like peptide-1 (GLP-1) receptor analogues, such as once-daily subcutaneous Liraglutide 3.0 mg (Saxenda
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Did the Preop Clinic Stop the Ozempic in Time? (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_3046;
Are there current ASA recommendations? What would you recommend be included in the algorithm?
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
PBLD360. Did the Preop Clinic Stop the Ozempic in Time? (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_3045;
What would you recommend be included in the algorithm? DESCRIPTION This Problem-Based Learning Discussion (PBLD) aims to delve into the multifaceted challenges encountered in the field of anesthesiology and offers an engaging platform for participants to deepen their understanding of anesthesiology challenges, share clinical experiences, and collaborate towards improving patient care outcomes.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Did the Preop Clinic Stop the Ozempic in Time? (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_1219;
Are there current ASA recommendations? What would you recommend be included in the algorithm?
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
PBLD207. Did the Preop Clinic Stop the Ozempic in Time? (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_1218;
What would you recommend be included in the algorithm? DESCRIPTION This Problem-Based Learning Discussion (PBLD) aims to delve into the multifaceted challenges encountered in the field of anesthesiology and offers an engaging platform for participants to deepen their understanding of anesthesiology challenges, share clinical experiences, and collaborate towards improving patient care outcomes.
- |||||||||| Mounjaro (tirzepatide) / Eli Lilly
Journal: Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). (Pubmed Central) - Jun 16, 2024
DESCRIPTION This Problem-Based Learning Discussion (PBLD) aims to delve into the multifaceted challenges encountered in the field of anesthesiology and offers an engaging platform for participants to deepen their understanding of anesthesiology challenges, share clinical experiences, and collaborate towards improving patient care outcomes. In this post hoc analysis, improvements in HbA1c and weight loss were consistent and significantly higher with tirzepatide, regardless of baseline ?-cell function and insulin resistance, compared with semaglutide.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction. (Pubmed Central) - Jun 13, 2024
Statistically significant improvements were also seen in the 6 min walk distance, levels of C-reactive protein, and N-terminal pro-B-type natriuretic peptide levels. Interestingly, the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity trial has shown that semaglutide produced a consistent reduction of around 20% vs. placebo across major cardiovascular event endpoints over the ?3-year follow-up in patients with overweight or obesity and cardiovascular disease but not diabetes.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Preclinical, Journal: Quantification of the effect of GLP-1R agonists on body weight using in (Pubmed Central) - Jun 13, 2024
The estimated reduction in EI of clinically relevant dosages of semaglutide (2.4?mg) and liraglutide (3.0?mg) was 34.5% and 13.0%, respectively...External validation showed the model was able to predict the effect of semaglutide on BW in the STEP 1 study. The GLP-1RA body composition model can be used to quantify and predict the effect of novel GLP-1R agonists on BW and changes in underlying processes using early in
- |||||||||| LAI287/semaglutide (NN1535) / Novo Nordisk
Review, Journal: IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective. (Pubmed Central) - Jun 10, 2024
IcoSema, a groundbreaking approach to diabetes management, combines insulin icodec and semaglutide to offer a transformative treatment option...This comprehensive article evaluates the potential of IcoSema from a clinical pharmacology perspective, examining the pharmacokinetics, efficacy, safety, compliance and cost-effectiveness of its individual components, as well as considering comparable combination therapies like iGlarLixi and IDegLira...Ongoing trials investigating IcoSema are expected to provide valuable insights into its efficacy, safety and comparative effectiveness. By addressing concerns such as potential side effects, individual patient response and drug interactions, healthcare providers can optimize treatment outcomes and enhance the management of type 2 diabetes.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal: The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. (Pubmed Central) - May 27, 2024
While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation. This calls for more extensive research to unravel the intricate relationships between the GLP-1R agonist and different cancers, providing valuable insights for clinicians and researchers alike.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. (Pubmed Central) - May 26, 2024
P3
The treatment benefit at 104?weeks for eGFR was 0.75?ml?min-1?1.73?m-2 (95% CI 0.43, 1.06; P?<?0.001) overall and 2.19?ml?min-1?1.73?m-2 (95% CI 1.00, 3.38; P?<?0.001) in patients with baseline eGFR <60?ml?min-1?1.73?m-2. These results suggest a benefit of semaglutide on kidney outcomes in individuals with overweight/obesity, without diabetes.ClinicalTrials.gov identifier: NCT03574597 .
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Real-World Impact of Once-Weekly Injectable Semaglutide on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes (Poster Hall (West A4-B2); 857) - May 20, 2024 - Abstract #ADA2024ADA_2861;
Additional research is needed to assess trends in utilization and adherence to minimize the risk of worsening socioeconomic disparities in pediatric obesity. Adults with T2D initiating sema OW had statistically significant decreases in weight, BMI and HbA1c after 1 year, with better weight outcomes in patients persistent to treatment and receiving maintenance dose ?1 mg.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
The Impact of Age on Response to Injectable Semaglutide (Poster Hall (West A4-B2); 791) - May 20, 2024 - Abstract #ADA2024ADA_2822;
Semaglutide is associated with HbA1c reductions across all ages. Weight reductions are also similar despite differences in baseline weight; this may be variably desirable in older individuals where weight maintenance may be preferred to prevent frailty.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Reducing Cardiometabolic Risk with Semaglutide in Type 1 Diabetes (RESET1) (Poster Hall (West A4-B2); 787) - May 20, 2024 - Abstract #ADA2024ADA_2818;
Weight reductions are also similar despite differences in baseline weight; this may be variably desirable in older individuals where weight maintenance may be preferred to prevent frailty. The RESET1 study will establish the effect of semaglutide on cardiometabolic health in adults with type 1 diabetes.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Once-Weekly Semaglutide in Patients with Peripheral Arterial Disease and Type 2 Diabetes (Poster Hall (West A4-B2); 784) - May 20, 2024 - Abstract #ADA2024ADA_2815;
Baseline medications are shown in table 1. We highlight the high CVD burden and the baseline medications of patients in STRIDE, representing a study population with multiple comorbid risk factors and reasonably well controlled T2D.
- |||||||||| Impact of Newer GLP-1 RAs on HbA1c in U.S. Adults with Type 2 Diabetes (Poster Hall (West A4-B2); 774) - May 20, 2024 - Abstract #ADA2024ADA_2804;
Increased adoption of newer GLP-1 RAs is associated with lower average HbA1c and higher proportion of HbA1c <7% at the population level. Population-level HbA1c control was improved after the first newer GLP-1 RA approval.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Therapeutic Efficacy of Monthly Semaglutide-Loaded Microsphere Injections in Zucker Diabetic Fatty Rats (Poster Hall (West A4-B2); 466) - May 20, 2024 - Abstract #ADA2024ADA_2762;
In pts with poorly controlled T2D, sema maintenance doses were associated with a considerable reduction in HbA1c and delay in insulin initiation in a 2-year follow-up, highlighting the importance of a maintenance dose in such pts. The Semaglutide microsphere injectables, administered monthly, showed the potential to substantially reduce the frequency of administrations compared to the commercial product, Ozempic
|
